Early evolocumab plus statin for large-artery ischemic stroke

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This prospective multicenter cohort will compare outcomes for patients with large-artery atherosclerotic ischemic stroke who receive early evolocumab plus a statin versus a statin alone. Adults 18–80 with LDL-C ≥1.8 mmol/L and symptom onset within 72 hours will be enrolled at the First Affiliated Hospital of Harbin Medical University and other centers in Heilongjiang Province and assigned to exposure cohorts based on the lipid-lowering treatment started in routine care. The evolocumab group receives 140 mg every 2 weeks or 420 mg monthly plus daily statin for 90 days while the non-exposed group receives daily statin alone for 90 days. Primary outcome is favorable functional outcome (mRS 0–2) at Day 90 with visits at baseline, Day 7, Day 30, and Day 90 and safety monitored through Day 90.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age 18-80 years.
2. Acute ischemic stroke diagnosed according to the Chinese Guidelines for Diagnosis and Treatment of Acute Ischemic Stroke (2023), based on clinical and imaging criteria.
3. Large-artery atherosclerotic subtype (TOAST classification) confirmed within 72 hours after stroke onset.
4. NIHSS score 4-20 before treatment.
5. Pre-stroke modified Rankin Scale (mRS) score ≤1.
6. LDL-C ≥1.8 mmol/L before enrollment.
7. Able to use evolocumab and statin medications in accordance with the physician's instructions and the prescribing information.
8. No prior use of a PCSK9 inhibitor before enrollment.
9. Written informed consent provided by the participant or legally authorized representative.

Exclusion Criteria:

1. Hemorrhagic transformation or other intracranial hemorrhage (including hemorrhagic infarction, subarachnoid hemorrhage, subdural hematoma, or epidural hematoma), except cerebral microbleeds detected only by SWI.
2. Prior intracranial or extracranial endovascular therapy before enrollment, planned acute endovascular therapy within 90 days, or planned surgery that may affect outcome assessment.
3. Severe cardiac insufficiency：NYHA class III or IV.
4. Severe hepatic dysfunction (ALT or AST \>3 x upper limit of normal) or severe renal dysfunction (serum creatinine \>2 mg/dL, eGFR \<30 mL/min/1.73 m2, or requiring dialysis).
5. Platelet count \<100 x 10\^9/L.
6. Pregnancy or breastfeeding.
7. Participation in another interventional clinical study within 30 days before enrollment, or concurrent participation in another interventional study that may affect outcome assessment.
8. Giant intracranial tumor, giant cerebral aneurysm, or arteriovenous malformation.
9. Active gastrointestinal ulcer, active bleeding tendency: corrected international normalized ratio (INR) \> 1.5, bleeding time exceeding the upper limit by more than 1 minute, or increased bleeding risk due to heparin-induced thrombocytopenia; major systemic bleeding occurring within 30 days prior to enrollment.
10. Pre-existing neurologic or psychiatric disease likely to affect neurologic or functional outcome assessment; severe neurologic deficit causing loss of independent living; dementia or psychiatric disease preventing completion of follow-up.
11. Autoimmune disease (for example systemic sclerosis, systemic lupus erythematosus, Sjogren syndrome, Behcet disease, mixed connective tissue disease, or IgG4-related disease).
12. Active seizures, hypotension, hyperthyroidism, asthma, and other allergic respiratory diseases, as well as individuals with a tendency toward allergies.
13. Any other condition judged by the investigator to make participation inappropriate or to pose substantial risk.

Where it's running

• Harbin, Heilongjiang, China, 150001
  Heilongjiang, China Recruiting

Study contacts

• Principal investigator: Zhongling Zhang — First Affiliated Hospital, Harbin Medical University
• Study coordinator: Zhongling Zhang
• Email: zhang777hyd@163.com
• Phone: +8613503615988

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Short-Term outside-in nerve stimulation for acute ischemic stroke

  This trial tests whether a 5-day external trigeminal nerve stimulation given after stroke can help more patients recover better than a sham treatment.

  Recruiting Xidian University · Xi'an · NCT07911605

• Sevoflurane vs. Propofol for anesthesia in stroke patients undergoing clot-removal

  This study tests whether sevoflurane or propofol used for anesthesia during endovascular treatment of an acute ischemic stroke affects the final brain damage and recovery.

  Recruiting Phase 3 Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau · Barcelona · NCT07902791

• Safety of adding NRICM301 to standard care for adults with acute ischemic stroke

  This study tests whether adding NRICM301, a traditional Chinese medicine formula, to usual care is safe for adults with acute ischemic stroke.

  Recruiting En Chu Kong Hospital · New Taipei City · NCT07900503

• Intracranial Recanalization with LT3001 in Acute Ischemic Stroke

  This phase II study tests whether LT3001 given to adults with acute ischemic stroke can help reopen blocked brain arteries.

  Recruiting Phase 2 Lumosa Therapeutics Co., Ltd. · Taichung · NCT07890298

• Mobilisation After Endovascular Stroke Treatment

  This study checks whether moving around 12 hours after endovascular stroke treatment is as safe as moving around 24 hours for people with an acute ischemic stroke.

  Recruiting at 2 sites Karolinska Institutet · Tampere and 1 other locations · NCT07860333

• Endovascular therapy plus standard care vs standard care alone for distal and medium vessel strokes

  In people with acute ischemic stroke due to distal or medium vessel blockages, this study tests whether adding endovascular treatment to the usual medical care helps improve outcomes compared with medical care alone.

  Recruiting Hospital Universitari Vall d'Hebron Research Institute · Barcelona, Barcelona · NCT07843797

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.